Effects of metformin on pregnancy outcomes in women with polycystic ovary syndrome: A meta-analysis
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
AIM: The aim of the study is to evaluate the effects of metformin on pregnancy outcomes in women with polycystic ovary syndrome (PCOS). METHODS: We searched electronic databases and bibliographies of relevant papers to identify studies comparing the pregnancy outcomes in the metformin group with those in the placebo or blank control group. Then, we did this meta-analysis based on the PRISMA guidelines. The primary outcomes included early pregnancy loss (EPL), preterm delivery, term delivery, and gestational diabetes mellitus (GDM). Secondary outcomes included pregnancy-induced hypertension (PIH), intrauterine growth restriction (IUGR), fetal malformation, vaginal delivery (VD), cesarean section (CS), and metformin's side effects, such as nausea or gastrointestinal discomfort. Certainly, data about neonatal death and macrosomia were analyzed if data available. RESULTS: Finally, 13 studies including 5 randomized controlled trials (RCT) and 8 cohort studies involving 1606 pregnant women with PCOS were analyzed. The pooled OR of EPL was 0.19 with obvious statistical significance, manifesting that metformin help to lower the rate of EPL (95% CI 0.12-0.28, P < 0.00001). Simultaneously, metformin showed the advantage of reducing the prevalence of preterm delivery (OR 0.37, 95% CI 0.20-0.68, P = 0.002). In addition, metformin could promote term delivery greatly and the pooled OR was 5.23 with sharp statistical difference (95% CI 3.12-8.75, P < 0.00001). CONCLUSION: Metformin treatment in women with PCOS throughout pregnancy could increase the possibility of term delivery, VD and reduce the risk of EPL, preterm labor, pregnancy complications such as GDM and PIH, with no serious side effects. Moreover, metformin was not teratogenic based on the limited data. So we may recommend metformin treatment for women with PCOS during the whole pregnancy period for it is quite beneficial and safe for both mothers and babies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Profound Peripheral Insulin Resistance, Independent of Obesity, in Polycystic Ovary Syndrome
Dunaif, A., Segal, K. R., Futterweit, W., & Dobrjansky, A. (1989) · Diabetes · doi:10.2337/diab.38.9.1165 · Cited by 1,967
Clinical pharmacokinetics of metformin
Graham, G. G., Punt, J., Arora, M., Day, R. O., Doogue, M. P., Duong, J. K., Furlong, T. J., Greenfield, J. R., Greenup, L. C., Kirkpatrick, C. M., et al. (2011) · Clinical Pharmacokinetics · doi:10.2165/11534750-000000000-00000 · Cited by 1,318 · cited 2×
“The half-life of metformin is 4 to 8hours and it is excreted through the kidneys.([9]) The most common adverse effects of metformin include gastrointestinal symptoms such as nausea, vomiting, and diarrhea, but they can be lightened or eliminated by taking the medication with food.”
BackgroundA meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome
Boomsma, C. M., Eijkemans, M. J. C., Hughes, E. G., Visser, G. H. A., Fauser, B. C. J. M., & Macklon, N. S. (2006) · Human Reproduction Update · doi:10.1093/humupd/dml036 · Cited by 852
Vanky, E., Stridsklev, S., Heimstad, R., Romundstad, P., Skogøy, K., Kleggetveit, O., Hjelle, S., von Brandis, P., Eikeland, T., Flo, K., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0853 · Cited by 315 · cited 9×
“Insulin sensitizers, such as metformin, may be beneficial in dealing with PCOS.”
MethodResultInfluentialPregnancy outcome after first-trimester exposure to metformin: a meta-analysis
Gilbert, C., Valois, M., & Koren, G. (2006) · Fertility and Sterility · doi:10.1016/j.fertnstert.2006.02.098 · Cited by 274
Morin-Papunen, L., Rantala, A. S., Unkila-Kallio, L., Tiitinen, A., Hippeläinen, M., Perheentupa, A., Tinkanen, H., Bloigu, R., Puukka, K., Ruokonen, A., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3061 · Cited by 243
Obstetric outcome in women with polycystic ovarian syndrome
Mikola, M. (2001) · Human Reproduction · doi:10.1093/humrep/16.2.226 · Cited by 206
Lautatzis, M.-E., Goulis, D. G., & Vrontakis, M. (2013) · Metabolism · doi:10.1016/j.metabol.2013.06.006 · Cited by 113
Zhuo, Z., Wang, A., & Yu, H. (2014) · Journal of Diabetes Research · doi:10.1155/2014/381231 · Cited by 55
Salvesen, K. Å., Vanky, E., & Carlsen, S. M. (2007) · Ultrasound in Obstetrics & Gynecology · doi:10.1002/uog.3965 · Cited by 48 · cited 1×
“90% 8 Salvesen et al([20]) N Y Y Y Y Y Y 95% 7 Fougner et al([21]) Y Y Y Y Y Y Y 95% 8 Morin-Papunen et al([22]) Y Y Y Y Y Y Y 80.”
Background
Cited by
Chronic Low Grade Inflammation in Pathogenesis of PCOS
Rudnicka, E., Suchta, K., Grymowicz, M., Calik-Ksepka, A., Smolarczyk, K., Duszewska, A. M., Smolarczyk, R., & Meczekalski, B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073789 · Cited by 680
Characteristics of obesity in polycystic ovary syndrome: Etiology, treatment, and genetics
Glueck, C. J., & Goldenberg, N. (2019) · Metabolism · doi:10.1016/j.metabol.2018.11.002 · Cited by 442
Polycystic ovary syndrome and mitochondrial dysfunction
Zhang, J., Bao, Y., Zhou, X., & Zheng, L. (2019) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-019-0509-4 · Cited by 258
The use of metformin in women with polycystic ovary syndrome: an updated review
Notaro, A. L. G., & Neto, F. T. L. (2022) · Journal of Assisted Reproduction and Genetics · doi:10.1007/s10815-022-02429-9 · Cited by 83
“Both MAs included studies with moderate to high risk of bias; therefore, their results should be taken with caution.”
BackgroundResultInfluentialBidhendi Yarandi, R., Behboudi-Gandevani, S., Amiri, M., & Ramezani Tehrani, F. (2019) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-019-0453-7 · Cited by 29
Metadata
- Authors
- Zeng, X.-L., Zhang, Y.-F., Tian, Q., Xue, Y., & An, R.-F.
- Venue
- Medicine
- Published
- 2016-09
- Volume
- 95
- Issue
- 36
- Pages
- e4526
- ISSN
- 0025-7974 (ISSN-L)
- OpenAlex
- W2508222951
- Cited by
- 76
- References
- 10
- FWCI
- 7.87
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of metformin on pregnancy outcomes in women with polycystic ovary syndrome: A meta-analysis. https://app.cochat.ai/papers/10.1097/md.0000000000004526
- The paper
- Zeng, X.-L., Zhang, Y.-F., Tian, Q., Xue, Y., & An, R.-F. (2016). Effects of metformin on pregnancy outcomes in women with polycystic ovary syndrome: A meta-analysis. Medicine. https://doi.org/10.1097/md.0000000000004526
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.